Bcl-B

Bcl-B (BCL2L10) is an atypical anti-apoptotic member of the BCL-2 family that primarily regulates mitochondrial apoptosis through selective interactions with pro-apoptotic proteins and intracellular survival pathways^[1][2]. Mechanistically, Bcl-B localizes mainly to the outer mitochondrial membrane, where it suppresses apoptosis by binding Bax, limiting mitochondrial outer membrane permeabilization and downstream caspase activation^[1][3]. Beyond canonical apoptosis control, Bcl-B also participates in autophagy, mitophagy, and Ca²⁺ signaling regulation through interactions with Beclin 1, Parkin, and the inositol 1,4,5-trisphosphate receptor (IP3R), linking mitochondrial homeostasis to cell survival programs^[1]. In disease models, dysregulated BCL2L10 expression has been reported in multiple malignancies, including melanoma, breast cancer, hepatocellular carcinoma, and hematologic cancers, where its biological role appears highly context dependent^[1][4]. In melanoma, BCL2L10 functions as a pro-survival factor that promotes resistance to cytotoxic agents and BCL-2 family-targeted therapies, supporting tumor cell survival under therapeutic stress^[4]. Compared with related anti-apoptotic isoforms such as BCL-2, BCL-xL, and MCL-1, Bcl-B exhibits a more restricted interaction profile, selectively binding Bax while showing limited interaction with several other BCL-2 family proteins, highlighting a distinct regulatory mechanism within the family^[1]. For experimental applications, the unique interaction network, context-dependent oncogenic activity, and potential sensitivity to proteasomal regulation have positioned Bcl-B as a candidate target for studies investigating apoptosis resistance and therapeutic response in cancer models^[1][4].